Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Julie Graff, ESMO 2019 – KEYNOTE-641 study in prostate cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 8th 2019

We met with Julie Graff (Knight Cancer Institute) at ESMO 2019 to discuss unmet needs in the treatment of metastatic castration-resistant prostate cancer and KEYNOTE-641 (NCT03834493), a phase III study of pembrolizumab plus enzalutamide in this patient population.

Questions
1.     What are the current unmet needs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor inhibitors? (0:05)
2.     Could you tell us a little about the aims and design of the KEYNOTE-641 study? (0:50)
3.     What are the eligibility criteria for this study? (1:23)
4.     How can we overcome the challenge of identifying biomarkers predictive of response to pembrolizumab? (1:55)
5.     What other combined therapeutic approaches involving androgen receptor inhibitors are being investigated in the treatment of mCRPC? (2:51)

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

Speaker disclosure: Julie Graff has received travel expenses from Sanofi.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup